Occam Dx
Occam Dx is a Netherlands-based medical technology company that has developed a portable point-of-care diagnostic platform using a patented nano-electronic biosensor to detect and count individual pathogens, targeting GP offices, emergency rooms, and ICUs with cartridge-based testing and cloud-connected microbiologist analysis.
- Company typePrivate
- Founded2019
- HeadquartersEnschede, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Occam Dx does
Occam Dx is a Dutch medical technology company developing a point-of-care infectious disease diagnostic platform built on a patented nano-electronic biosensor. The system is designed to detect and count individual virus or bacterium particles directly from bodily fluid samples without the amplification step required by conventional microbiology, positioning the company as introducing what it describes as '22nd century diagnostics.' The platform comprises three integrated components: a portable SPOC instrument deployed at point-of-care sites, single-use cartridges each containing a predetermined pathogen panel for one patient, and cloud-based software that transmits test data to remote microbiologists for real-time diagnostic analysis.
The technology is rooted in proprietary bio-functionalization and signal processing capable of probing individual antibody/antigen interactions at very small analyte sizes. Occam Dx targets point-of-care healthcare settings including GP offices, emergency rooms, and ICUs where it seeks to replace expensive, slow, and labor-intensive conventional microbiology workflows with a faster, more accessible, and cost-effective procedure. The company is currently seeking Series A capital and is actively recruiting US-based partners for medical pilots, including contract research organizations for technology validation, microbiologists for use case development, and healthcare corporates for implementation. Headquartered at the University of Twente campus in Enschede, Netherlands, Occam Dx operates with a leadership team that includes a CEO and CTO alongside academic advisors from the University of Twente.
Occam Dx firmographics
Firmographics- Name
- Occam Dx
- Legal name
- Occam Dx
- Website
- https://occamdx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Occam Dx is a Netherlands-based medical technology company that has developed a portable point-of-care diagnostic platform using a patented nano-electronic biosensor to detect and count individual pathogens, targeting GP offices, emergency rooms, and ICUs with cartridge-based testing and cloud-connected microbiologist analysis.
- Ownership category
- akta.pro rank
Occam Dx industry classification
Industry- Product category
- Point-of-care infectious disease diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA)
- akta.pro secondary industries
- Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels) (HLAHAOAJ), Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)
Keywords
Where Occam Dx is headquartered
LocationHeadquarters
- HQ city
- Enschede
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Occam Dx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- SPOC Instrument subscription: The SPOC instrument is provided under a subscription model, with one device per point-of-care location. The instrument is portable and designed for use at GP offices, emergency rooms, and other clinical settings.
- Single-use cartridge sales: Single-use disposable cartridges sold on a per-patient basis, each containing a predetermined pathogen panel. This creates recurring consumable revenue alongside the instrument subscription.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | SPOC Instrument subscription |
| Unit Pricing | Pay-as-you-go | Cartridge (single-use) |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Occam Dx product offering
Product offeringCore offering
Occam Dx offers a point-of-care diagnostic platform comprising the portable SPOC Instrument, single-use pathogen-panel cartridges, and a cloud-based software platform. The system uses a proprietary nano-electronic biosensor to detect and count individual virus and bacterium particles in bodily fluids without amplification, transmitting data via the cloud to remote microbiologists for real-time diagnosis in GP offices, emergency rooms, and ICUs.
Product overview
Occam Dx offers a diagnostic platform consisting of three integrated components: a portable SPOC Instrument for point-of-care testing, single-use Cartridges with predetermined pathogen panels, and cloud-based Software connecting caregivers, patients, and microbiologists. The system uses a proprietary nano-electronic biosensor to detect and count individual pathogens in bodily fluids, enabling rapid, reliable diagnosis at GP offices, emergency rooms, and ICUs with real-time microbiologist analysis.
Differentiator
Problem solved
Functional benefit
Products and services
- SPOC Instrument
- Cartridge
- Software Platform
Quantifiable outcome
- Detect single virus or bacterium particles
- +2 more outcomes
Companies that use Occam Dx
Customer profileSegments4 records
Ideal customer profiles2 records
Occam Dx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Occam Dx partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights5 records
Occam Dx competitors and assessment
Company assessmentBroad incumbents
- DiaSorin (Liaison/MDx): European-headquartered diagnostics incumbent offering a broad infectious-disease menu including POCT molecular and immunoassay solutions. Comparable as an established European diagnostics player with overlapping ID testing portfolios.
- Hologic (Panther Fusion / Novodiag): Broad molecular diagnostics incumbent with Panther Fusion for high-throughput and Novodiag for cartridge-based near-patient testing. Comparable as a large incumbent offering cartridge-based molecular panels.
- Abbott (ID NOW / Panbio): Abbott's ID NOW molecular POCT and rapid antigen tests dominate near-patient infectious disease testing globally. Comparable as a broad incumbent offering POCT solutions across the same point-of-care customer segments.
Direct peers
- Qiagen (QIAstat-Dx): QIAstat-Dx is a cartridge-based syndromic POCT system used in ER/ICU for respiratory, GI, and meningitis panels. Closely matches Occam's cartridge + instrument architecture and syndromic panel positioning.
- Cepheid (Danaher): Market-leading molecular POCT platform (GeneXpert) deployed in GP, ER, and ICU settings for infectious disease testing. Directly comparable to Occam Dx's SPOC in target customer, point-of-care use case, and infectious-disease menu focus.
- bioMérieux (BioFire): FilmArray syndromic panels are the gold standard for multiplex infectious-disease POCT in hospitals and emergency settings. Directly comparable as a cartridge-based, predetermined-panel, point-of-care platform.
- Mesa Biotech (Now part of Mesa Labs): Developer of the Accula molecular POCT system for infectious disease (flu, RSV, Strep A, SARS-CoV-2). Comparable as a small cartridge-based POCT targeting CLIA-waived and near-patient settings.
Emerging players
- T2 Biosystems: T2 Magnetic Resonance diagnostics platform for direct-from-sample detection without amplification. Conceptually comparable to Occam's amplification-free single-particle detection approach, though focused on sepsis and Candida.
- QuantuMDx: UK-based developer of Q-POC, a portable molecular POCT device targeting infectious disease at point of care. Highly comparable as an emerging nano/molecular POCT competitor with similar form factor and global health ambitions.
- binx health: Developer of the binx io molecular POCT platform, primarily focused on CT/NG STI testing at point of care. Comparable as an emerging cartridge-based rapid molecular POC player in infectious disease.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks4 records
Key highlights6 records
Customer concentration
Occam Dx social profiles
Digital presenceOccam Dx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Occam Dx leadership team
Management profileNumber of profiles
Profiles8 records
Occam Dx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Occam Dx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Occam Dx
What does Occam Dx do?
Occam Dx offers a point-of-care diagnostic platform comprising the portable SPOC Instrument, single-use pathogen-panel cartridges, and a cloud-based software platform. The system uses a proprietary nano-electronic biosensor to detect and count individual virus and bacterium particles in bodily fluids without amplification, transmitting data via the cloud to remote microbiologists for real-time diagnosis in GP offices, emergency rooms, and ICUs.
Is Occam Dx a public or private company?
Occam Dx is a private company. It is classified as unknown and is currently operating.
When was Occam Dx founded?
Occam Dx was founded in 2019. It employs 1 to 10 people.
Where is Occam Dx based?
Occam Dx is headquartered in Enschede, Netherlands, in the Europe region.
How does Occam Dx make money?
Two revenue lines are on record. SPOC Instrument subscription is the primary driver. The others are single-use cartridge sales.
Who are Occam Dx's main competitors?
Broad incumbents on record are DiaSorin (Liaison/MDx), Hologic (Panther Fusion / Novodiag) and Abbott (ID NOW / Panbio). Direct peers are Qiagen (QIAstat-Dx), Cepheid (Danaher), bioMérieux (BioFire) and Mesa Biotech (Now part of Mesa Labs). Emerging players are T2 Biosystems, QuantuMDx and binx health.
Does Occam Dx have an API?
No public API is recorded for Occam Dx.
What industry is Occam Dx in?
Occam Dx's product category is Point-of-care infectious disease diagnostics. Its primary akta.pro industry code is HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis), with a secondary code of HLAHAOAJ, Multiplex Syndromic POCT Panels (Respiratory/GI/meningitis panels). Its NAICS code is 325413 and its SIC code is 2835.